6505--Flyrcado F18 Flurpiridaz Radiopharmaceutical Injection
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), specifically Network Contracting Office 17 (NCO-17), has awarded a firm-fixed price contract to Medi-Physics, Inc. (doing business as GE Healthcare) for Flyrcado™ (flurpiridaz F-18) Injection. The award, valued at $378,090.90, was made on February 10, 2026, under a sole source justification.
Scope of Work
This contract covers the procurement of 990 mCi of Flyrcado™ (flurpiridaz F-18) Injection. This radiopharmaceutical is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress conditions. Its purpose is to evaluate for myocardial ischemia and infarction in patients with known or suspected coronary artery disease (CAD) within the VA North Texas and South Texas Health Care Systems.
Contract & Timeline
- Contract Type: Firm-Fixed Price
- Awardee: Medi-Physics, Inc. (UEI: CETPVZL5RQS3)
- Award Amount: $378,090.90
- Award Date: February 10, 2026
- Period of Performance: Delivery Dates: February 10, 2026 – February 9, 2027
- Justification: Other than full and open competition, authorized under 41 U.S.C. §3304(a)(1) as implemented by FAR 6.302-1, citing only one responsible source.
Additional Notes
Market research confirmed that Medi-Physics, Inc. is the sole manufacturer of Flyrcado™. A notice of intent for this sole source procurement was posted on SAM.gov on January 5, 2026, and no responses were received from other potential sources. The contracting officer determined the cost to be fair and reasonable based on typical pricing for VA pharmaceutical contracts.